Leucine Rich Bio Pvt Ltd, a Bengaluru-based bioinformatics company, has announced alliance partnership with New-Delhi’s  NextGen Life Sciences to market its  products and services in the Indian market.

While Leucine operates in a niche domain of NGS data analysis and provides  ‘software as a service’ utilizing its proprietary in- house developed Human Genome Analysis, Interpretation & Reporting platform called AGIS (Advanced Genome Interpretation Suite), NextGen Life is a leading distributor of innovative biological products and services for the Life science research and diagnostic market.

AGIS uses an intuitive ranking system to identify clinically relevant variants. It  annotates variants from multiple knowledge bases including Leucine Rich Bio’s Human Genome Variation Database (LRB-HGVD).

LRB plans to launch AGIS for clinics and diagnostics wherein it would cater to the developing field of ‘personalized genomics’ thereby providing the clinician with actionable mutation analysis. The clinical report contains relevant information that is needed to make clinical decisions. Clinical reports are tailored to provide highly ranked disease-causing or clinically pathogenic variants. The report will also contain variants related to pharmacogenomics.

Currently, LRB is involved in providing NGS data analysis service pertaining to whole genome, exome, transcriptome and small RNA sequencing.

According to the MoU signed between LRB and NextGen Life Sciences, the latter  which handles multinational companies like Thermo Fisher, DSS Takara Bio and Germany based HighQu GmbH in its portfolio, would provide its market depth and field penetration in the Indian market to promote LRB’s products and services.

According to  Dr Debojyoti Dhar, director (business development and innovation), LRB getting NextGen Life Sciences on board at this stage is important for us. “We feel that the  two companies can complement look forward to a mutually rewarding association.

 “Our  experience in the Indian life sciences market makes us confident that we will successfully integrate LRB products and services in India and grow the  business further together. We are in an even stronger position to help our customers to achieve their goals for innovation and productivity. Our combine offerings will enable  accelerate life sciences research and improve human health,” said Dr Nagma Abbasi, MD, NextGen Life Sciences.